Piper Jaffray analyst Sean Wieland raised his price target for Medidata Solutions to $98 after spending time with management. The company is the leader in electronic data capture for clinical trials and is leveraging its position to pursue adjacent opportunities in machine learning and analytics, Wieland tells investors in a research note. He believes Medidata is becoming the de facto standard for clinical data analysis and collaboration, and that today's high-teens growth rate is sustainable. The analyst reiterates an Overweight rating on the shares.